Logo for Savara Inc

Savara Inc Investor Relations Material

Latest events

Logo for Savara Inc

Q3 2024

12 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Savara Inc

Access all reports
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's main focus is on advancing its lead product candidate, molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In addition to molgramostim, Savara is also developing AeroVanc, an inhaled vancomycin aimed at treating methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. Savara is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.